Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi to Develop Principia’s Multiple Sclerosis Candidate | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Sanofi to Develop Principia’s Multiple Sclerosis Candidate

Sanofi will pay $40 million upfront plus future milestones

By: Betsy Louda

, Contract Pharma

Sanofi has agreed to develop Principia Biopharma Inc.‘s experimental oral treatment that shows promise in multiple sclerosis and, potentially, other central nervous system diseases.

 

The treatment, Bruton’s tyrosine kinase inhibitor (PRN2246), is designed to access the brain and spinal cord by crossing the blood-brain barrier and impact immune cell and brain cell signaling. 

 

Under the deal, Sanofi will pay a $40 million upfront payment, along with future milestone payments that could total $765 million and royalties on product sales. In return, Principia is granting Sanofi an exclusive, worldwide license to develop and commercialize PRN2246. 

 

“Sanofi is an ideal partner for PRN2246. The agreement allows Principia to maximize the BTK opportunity in neurology with a strong partner for PRN2246 while focusing internal resources on our lead BTK inhibitor in another therapeutic area,” said Martin Babler, chief executive officer of Principia Biopharma.

 

The transaction is expected to close in the fourth quarter of 2017.

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters